Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadruple oral therapy versus metformin dose escalation in inadequately controlled type 2 diabetes
KCT0009804Phase 4Completed
- Sponsor
- HK inno.N Corporation
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of gemigliptin, sitagliptin, dapagliflozin, lobeglitazone, metformin in type 2 diabetes mellitus (T2DM), sponsored by HK inno.N Corporation. Started Oct 2024; status: completed.
02
Drugs
gemigliptinsitagliptindapagliflozinlobeglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0009804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009804.